Huxley Health Inc. Introduces Aerasyn Biotech Division, Expands Leadership and Scalable IP Platform, Engages Capital Partner for Up to $15M Financing and Prepares to Go Public Amid Growing U.S. Policy and Public Discourse on Psychedelics

Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - Huxley Health Inc. ("Huxley" or the "Company"), together with its Aerasyn Biotech division, a biotechnology platform advancing next-generation therapeutics through AI-guided discovery, advanced synthesis, and proprietary formulation technologies, today announced a series of coordinated strategic developments that significantly strengthen its leadership team, intellectual property platform, and capital markets positioning. These...

2026-04-20 7:30 AM EDT

Ready to Announce with Confidence?

Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Huxley Health Inc.

Our Mission: We've built a vertically integrated platform that enables the scalable development of safer, more precise psychedelic-derived therapeutics. By addressing critical bottlenecks across discovery, formulation, and manufacturing, we accelerate the path from innovation to patient impact.

Recent News

Huxley Health Inc. Introduces Aerasyn Biotech Division, Expands Leadership and Scalable IP Platform, Engages Capital Partner for Up to $15M Financing and Prepares to Go Public Amid Growing U.S. Policy and Public Discourse on Psychedelics

Ready to Announce with Confidence?